Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
22,273,676
-
Shares change
-
+2,926
-
Total reported value, excl. options
-
$330,912,225
-
Value change
-
-$1,999,524
-
Put/Call ratio
-
180%
-
Number of buys
-
53
-
Number of sells
-
-62
-
Price
-
$14.85
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q3 2021
171 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q3 2021.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,273,676 shares
.
Largest 10 shareholders include STATE STREET CORP (3,145,441 shares), VANGUARD GROUP INC (2,830,263 shares), FMR LLC (2,566,430 shares), BlackRock Inc. (2,363,463 shares), Point72 Asset Management, L.P. (698,700 shares), EULAV Asset Management (660,000 shares), Samsara BioCapital, LLC (640,688 shares), MACQUARIE GROUP LTD (621,412 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (534,176 shares), and GEODE CAPITAL MANAGEMENT, LLC (497,636 shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.